Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : John, Mike & Tom's Wild World of Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Original Mad Dog who wrote (595)	3/23/2000 8:42:00 AM
From: wlheatmoon	Read Replies (1) \| Respond to of 2850

FYI--BGEN will also take a hit today. biz.yahoo.com However he said Biogen Inc could come under pressure after it lost an arbitration case against Schering Plough Corp (NYSE:SGP - news) over calculating royalty payments on sales of Schering's hepatitis C treatment Rebetron. The arbitration decision holds that Biogen is only entitled to royalties on the sales of Intron A -- one of two components of Rebetron -- whether sold alone or as part of the Rebetron package.